Concepts (271)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatectomy | 39 | 2022 | 61 | 10.560 |
Why?
|
| Liver Neoplasms | 31 | 2022 | 103 | 9.490 |
Why?
|
| Portal Vein | 30 | 2022 | 46 | 8.420 |
Why?
|
| Liver | 21 | 2022 | 148 | 6.640 |
Why?
|
| Liver Regeneration | 17 | 2022 | 24 | 4.870 |
Why?
|
| Colorectal Neoplasms | 13 | 2021 | 112 | 3.330 |
Why?
|
| Ligation | 22 | 2022 | 38 | 2.440 |
Why?
|
| Embolization, Therapeutic | 6 | 2021 | 59 | 2.210 |
Why?
|
| Laparoscopy | 6 | 2021 | 188 | 1.620 |
Why?
|
| Hepatic Stellate Cells | 2 | 2020 | 3 | 1.280 |
Why?
|
| Postoperative Complications | 13 | 2022 | 928 | 1.240 |
Why?
|
| Liver Diseases | 2 | 2018 | 34 | 1.100 |
Why?
|
| Cause of Death | 3 | 2017 | 65 | 1.030 |
Why?
|
| Registries | 9 | 2019 | 199 | 1.020 |
Why?
|
| Humans | 56 | 2024 | 27214 | 0.950 |
Why?
|
| Liver Failure | 4 | 2019 | 10 | 0.930 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2021 | 25 | 0.880 |
Why?
|
| Treatment Outcome | 20 | 2021 | 3525 | 0.830 |
Why?
|
| Hypoxia | 2 | 2020 | 32 | 0.790 |
Why?
|
| Hypertrophy | 5 | 2022 | 24 | 0.790 |
Why?
|
| Organ Size | 9 | 2019 | 95 | 0.740 |
Why?
|
| Sarcopenia | 1 | 2021 | 31 | 0.710 |
Why?
|
| Male | 36 | 2021 | 14852 | 0.710 |
Why?
|
| Retrospective Studies | 17 | 2022 | 3547 | 0.690 |
Why?
|
| Neovascularization, Pathologic | 1 | 2020 | 36 | 0.660 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 78 | 0.650 |
Why?
|
| Kidney Transplantation | 5 | 2021 | 119 | 0.640 |
Why?
|
| Middle Aged | 26 | 2019 | 9057 | 0.620 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 12 | 0.620 |
Why?
|
| Hepatomegaly | 1 | 2018 | 7 | 0.610 |
Why?
|
| Reperfusion Injury | 1 | 2018 | 6 | 0.610 |
Why?
|
| Neuroendocrine Tumors | 5 | 2019 | 53 | 0.610 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 261 | 0.600 |
Why?
|
| Publication Bias | 1 | 2018 | 5 | 0.590 |
Why?
|
| Female | 31 | 2021 | 15308 | 0.580 |
Why?
|
| Oxidative Stress | 1 | 2018 | 93 | 0.580 |
Why?
|
| Antioxidants | 1 | 2018 | 66 | 0.580 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 117 | 0.580 |
Why?
|
| Bibliometrics | 1 | 2018 | 30 | 0.580 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 25 | 0.550 |
Why?
|
| Length of Stay | 5 | 2021 | 321 | 0.520 |
Why?
|
| Pancreatic Neoplasms | 4 | 2024 | 94 | 0.510 |
Why?
|
| Therapies, Investigational | 1 | 2016 | 5 | 0.510 |
Why?
|
| Aged | 20 | 2019 | 9113 | 0.510 |
Why?
|
| Animals | 8 | 2021 | 3630 | 0.470 |
Why?
|
| Catheter Ablation | 1 | 2015 | 60 | 0.450 |
Why?
|
| Graft Rejection | 4 | 2008 | 69 | 0.440 |
Why?
|
| Liver Transplantation | 3 | 2015 | 92 | 0.430 |
Why?
|
| Hepatic Veins | 4 | 2022 | 11 | 0.410 |
Why?
|
| Time Factors | 9 | 2019 | 1438 | 0.410 |
Why?
|
| Blood Loss, Surgical | 3 | 2019 | 56 | 0.410 |
Why?
|
| Prognosis | 8 | 2020 | 804 | 0.400 |
Why?
|
| Risk Factors | 10 | 2019 | 2336 | 0.400 |
Why?
|
| Feasibility Studies | 4 | 2016 | 214 | 0.380 |
Why?
|
| Operative Time | 4 | 2019 | 92 | 0.350 |
Why?
|
| Survival Rate | 6 | 2018 | 344 | 0.340 |
Why?
|
| Follow-Up Studies | 7 | 2018 | 1802 | 0.330 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 140 | 0.330 |
Why?
|
| Models, Animal | 3 | 2020 | 109 | 0.320 |
Why?
|
| Tissue Donors | 2 | 2021 | 79 | 0.320 |
Why?
|
| Neoplasm Staging | 5 | 2018 | 368 | 0.320 |
Why?
|
| Random Allocation | 3 | 2018 | 123 | 0.320 |
Why?
|
| Isoantibodies | 2 | 2006 | 7 | 0.310 |
Why?
|
| Intestinal Neoplasms | 2 | 2018 | 13 | 0.300 |
Why?
|
| Antibodies, Neoplasm | 1 | 2008 | 12 | 0.290 |
Why?
|
| Stomach Neoplasms | 2 | 2018 | 34 | 0.290 |
Why?
|
| Swine | 2 | 2018 | 73 | 0.290 |
Why?
|
| Pancreas Transplantation | 2 | 2021 | 17 | 0.290 |
Why?
|
| Death | 1 | 2008 | 47 | 0.290 |
Why?
|
| Adult | 15 | 2019 | 7938 | 0.280 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 24 | 0.280 |
Why?
|
| Patient Selection | 4 | 2018 | 197 | 0.270 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 178 | 0.270 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 120 | 0.270 |
Why?
|
| Rats, Wistar | 2 | 2017 | 54 | 0.270 |
Why?
|
| Rats | 2 | 2020 | 660 | 0.260 |
Why?
|
| Switzerland | 3 | 2021 | 8 | 0.260 |
Why?
|
| Risk Assessment | 5 | 2019 | 630 | 0.250 |
Why?
|
| Plasmapheresis | 1 | 2006 | 13 | 0.250 |
Why?
|
| HLA Antigens | 1 | 2006 | 14 | 0.250 |
Why?
|
| Antibody Formation | 1 | 2006 | 18 | 0.250 |
Why?
|
| Philosophy, Medical | 1 | 2004 | 3 | 0.230 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2024 | 6 | 0.220 |
Why?
|
| Spirituality | 1 | 2004 | 80 | 0.210 |
Why?
|
| Tissue and Organ Procurement | 3 | 2012 | 35 | 0.200 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 893 | 0.200 |
Why?
|
| Ultrasonography | 3 | 2021 | 226 | 0.190 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 331 | 0.190 |
Why?
|
| Cell Proliferation | 2 | 2020 | 182 | 0.190 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 13 | 0.190 |
Why?
|
| Databases, Factual | 3 | 2019 | 352 | 0.190 |
Why?
|
| Biomarkers | 3 | 2020 | 561 | 0.180 |
Why?
|
| Organ Transplantation | 1 | 2021 | 32 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 24 | 0.180 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 202 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2021 | 54 | 0.180 |
Why?
|
| Hospitals | 1 | 2021 | 170 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 124 | 0.170 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2020 | 1 | 0.170 |
Why?
|
| Adrenalectomy | 1 | 2019 | 5 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 70 | 0.160 |
Why?
|
| Brazil | 2 | 2016 | 43 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 15 | 0.160 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 83 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 16 | 0.160 |
Why?
|
| Hospital Mortality | 3 | 2015 | 141 | 0.160 |
Why?
|
| Parenchymal Tissue | 1 | 2019 | 2 | 0.160 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 3 | 0.160 |
Why?
|
| Liver Function Tests | 4 | 2017 | 21 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2019 | 17 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2019 | 82 | 0.150 |
Why?
|
| Gallium Radioisotopes | 1 | 2018 | 4 | 0.150 |
Why?
|
| Paracrine Communication | 1 | 2018 | 4 | 0.150 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2018 | 11 | 0.150 |
Why?
|
| Culture Media, Conditioned | 1 | 2018 | 19 | 0.150 |
Why?
|
| Organometallic Compounds | 1 | 2018 | 17 | 0.150 |
Why?
|
| Cytoprotection | 1 | 2018 | 9 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 19 | 0.150 |
Why?
|
| Hepatocytes | 1 | 2018 | 11 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2018 | 24 | 0.150 |
Why?
|
| Anesthesia | 1 | 2018 | 29 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 36 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 46 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 37 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 667 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 46 | 0.150 |
Why?
|
| Models, Biological | 1 | 2020 | 320 | 0.140 |
Why?
|
| Pulmonary Embolism | 1 | 2019 | 63 | 0.140 |
Why?
|
| Logistic Models | 3 | 2016 | 398 | 0.140 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 265 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 261 | 0.140 |
Why?
|
| Portal Pressure | 1 | 2017 | 4 | 0.140 |
Why?
|
| Liver Circulation | 1 | 2017 | 5 | 0.140 |
Why?
|
| Gastric Bypass | 1 | 2018 | 69 | 0.140 |
Why?
|
| Apoptosis | 1 | 2018 | 211 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2017 | 26 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 291 | 0.140 |
Why?
|
| Hyperplasia | 1 | 2017 | 19 | 0.140 |
Why?
|
| Melanoma | 1 | 2017 | 59 | 0.130 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 673 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2016 | 11 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 7 | 0.130 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 7 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2018 | 448 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 172 | 0.130 |
Why?
|
| Obesity | 1 | 2018 | 309 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 601 | 0.120 |
Why?
|
| Primary Graft Dysfunction | 1 | 2015 | 5 | 0.120 |
Why?
|
| Methyl Ethers | 1 | 2015 | 6 | 0.120 |
Why?
|
| Propofol | 1 | 2015 | 8 | 0.120 |
Why?
|
| Anesthetics, Intravenous | 1 | 2015 | 9 | 0.120 |
Why?
|
| Anesthetics, Inhalation | 1 | 2015 | 12 | 0.120 |
Why?
|
| Transplantation Conditioning | 1 | 2015 | 39 | 0.120 |
Why?
|
| Cohort Studies | 3 | 2017 | 1903 | 0.120 |
Why?
|
| Safety | 1 | 2014 | 37 | 0.120 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 110 | 0.120 |
Why?
|
| Surgeons | 1 | 2016 | 88 | 0.110 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 93 | 0.110 |
Why?
|
| Viscera | 1 | 2013 | 2 | 0.110 |
Why?
|
| Vascular Patency | 1 | 2013 | 17 | 0.110 |
Why?
|
| Renal Artery | 1 | 2013 | 8 | 0.100 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 13 | 0.100 |
Why?
|
| Aneurysm | 1 | 2013 | 10 | 0.100 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Endovascular Procedures | 1 | 2013 | 32 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2012 | 65 | 0.100 |
Why?
|
| Stents | 1 | 2013 | 81 | 0.100 |
Why?
|
| Linear Models | 1 | 2012 | 247 | 0.100 |
Why?
|
| Bilirubin | 2 | 2016 | 11 | 0.090 |
Why?
|
| Resource Allocation | 1 | 2011 | 4 | 0.090 |
Why?
|
| Health Care Rationing | 1 | 2011 | 6 | 0.090 |
Why?
|
| End Stage Liver Disease | 1 | 2011 | 12 | 0.090 |
Why?
|
| Liver Cirrhosis | 2 | 2012 | 44 | 0.080 |
Why?
|
| Histocompatibility Testing | 1 | 2009 | 2 | 0.080 |
Why?
|
| HLA-C Antigens | 1 | 2009 | 10 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2019 | 179 | 0.070 |
Why?
|
| Antilymphocyte Serum | 1 | 2008 | 2 | 0.070 |
Why?
|
| Alemtuzumab | 1 | 2008 | 4 | 0.070 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2008 | 7 | 0.070 |
Why?
|
| Kidney Failure, Chronic | 1 | 2009 | 127 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 39 | 0.070 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2007 | 3 | 0.070 |
Why?
|
| Blood Vessels | 1 | 2007 | 14 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2008 | 46 | 0.070 |
Why?
|
| Graft Survival | 1 | 2008 | 97 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2007 | 30 | 0.070 |
Why?
|
| Cytomegalovirus Infections | 1 | 2008 | 35 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 87 | 0.070 |
Why?
|
| Incidence | 2 | 2021 | 763 | 0.070 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2007 | 116 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2017 | 4842 | 0.060 |
Why?
|
| HLA-DP Antigens | 1 | 2006 | 1 | 0.060 |
Why?
|
| Complement C4b | 1 | 2006 | 1 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2018 | 462 | 0.060 |
Why?
|
| Peptide Fragments | 1 | 2006 | 76 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2021 | 1784 | 0.060 |
Why?
|
| Religion and Medicine | 1 | 2004 | 25 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 1105 | 0.060 |
Why?
|
| Anesthesia, Intravenous | 1 | 2024 | 5 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2024 | 24 | 0.050 |
Why?
|
| Hospitals, University | 2 | 2018 | 23 | 0.050 |
Why?
|
| Delphi Technique | 1 | 2022 | 28 | 0.050 |
Why?
|
| Consensus | 1 | 2022 | 92 | 0.050 |
Why?
|
| Mice | 2 | 2021 | 1416 | 0.050 |
Why?
|
| Benzofurans | 1 | 2021 | 5 | 0.050 |
Why?
|
| Naphthoquinones | 1 | 2021 | 5 | 0.050 |
Why?
|
| Aniline Compounds | 1 | 2021 | 35 | 0.050 |
Why?
|
| Transplant Recipients | 1 | 2021 | 22 | 0.050 |
Why?
|
| Sulfonamides | 1 | 2021 | 44 | 0.040 |
Why?
|
| Pancreas | 1 | 2021 | 33 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 64 | 0.040 |
Why?
|
| Cold Ischemia | 2 | 2011 | 3 | 0.040 |
Why?
|
| Kidney | 1 | 2021 | 152 | 0.040 |
Why?
|
| Mitotane | 1 | 2019 | 4 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 119 | 0.040 |
Why?
|
| United States | 2 | 2018 | 2076 | 0.040 |
Why?
|
| Argentina | 1 | 2019 | 1 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2019 | 14 | 0.040 |
Why?
|
| Digestive System Neoplasms | 1 | 2018 | 5 | 0.040 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2018 | 16 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 57 | 0.040 |
Why?
|
| Serum Albumin | 1 | 2019 | 25 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 305 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2018 | 7 | 0.040 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 12 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2018 | 105 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2019 | 88 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 245 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2017 | 43 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 24 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2022 | 1156 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2019 | 334 | 0.030 |
Why?
|
| Edema | 1 | 2017 | 25 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2017 | 159 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 103 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 79 | 0.030 |
Why?
|
| Rabbits | 1 | 2017 | 180 | 0.030 |
Why?
|
| Italy | 1 | 2016 | 15 | 0.030 |
Why?
|
| Age Factors | 1 | 2018 | 776 | 0.030 |
Why?
|
| Medical Audit | 1 | 2016 | 5 | 0.030 |
Why?
|
| Hospitals, High-Volume | 1 | 2016 | 8 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 374 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 218 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2016 | 64 | 0.030 |
Why?
|
| Belgium | 1 | 2015 | 1 | 0.030 |
Why?
|
| Aspartate Aminotransferases | 1 | 2015 | 14 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 87 | 0.030 |
Why?
|
| Sarcoma | 1 | 2017 | 148 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 350 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2016 | 478 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 277 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 551 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2013 | 19 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 411 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 589 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2011 | 18 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 70 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2011 | 58 | 0.020 |
Why?
|
| Immunization | 1 | 2009 | 13 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2009 | 14 | 0.020 |
Why?
|
| Algorithms | 1 | 2012 | 352 | 0.020 |
Why?
|
| Child | 1 | 2012 | 1268 | 0.020 |
Why?
|
| Histocompatibility | 1 | 2007 | 3 | 0.020 |
Why?
|
| Receptors, CXCR3 | 1 | 2007 | 4 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 23 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2007 | 279 | 0.020 |
Why?
|
| Wisconsin | 1 | 2006 | 3 | 0.020 |
Why?
|
| Kidney Tubules | 1 | 2006 | 6 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2006 | 40 | 0.020 |
Why?
|
| Atrophy | 1 | 2006 | 87 | 0.020 |
Why?
|